Boston Scientific beats Wall Street's expectations and its own forecasts for 2nd-quarter sales and earnings, with strong performances from its core implantable cardiac defibrillator and drug-eluting stent businesses.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1Ab8pCF
Cap comentari:
Publica un comentari a l'entrada